Unicycive Therapeutics, Inc. (UNCY) Stock Grade

About Unicycive Therapeutics, Inc.'s fundamentals

Unicycive Therapeutics is a biotechnology company with a market capitalization of $916.7 million that reported no revenue growth year-over-year and maintained a net margin of 0%, reflecting a net loss in its latest annual statement. The company does not pay a dividend to shareholders. Standard valuation metrics like P/E ratio and return on equity are not applicable given the company's current loss-making position.